Expanded Access Program (EAP)

There are patients with life-threatening conditions who are not able or are ineligible to participate in clinical trials, despite the absence of efficacious treatment.
Daiichi Sankyo provides an option to give access to investigational products for reasons that include “compassionate use.” This program allows access to investigational products for these patients.
Establishing Expanded Access Program (EAP) for Daiichi Sankyo investigational products will be approved only if all criteria are met including full assessment of expected therapeutic benefits and risks associated with the use of the products, on the premise that the development of the pharmaceuticals will not be adversely impacted.

Expanded Access Program